Beam stock launched to a year high Tuesday as enthusiasm grows for its next-generation form of gene editing. Please watch the video at Investors.com - CRSP Stock On Wild Ride After FDA's Historic ...

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on BEAM stock, giving a Hold rating on February 27. Mani Foroohar’s rating is based on a thorough evaluation of Beam ...

Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to ...

Beam Therapeutics shares were up 31% to $47.02 after the company reported fourth-quarter earnings that beat analysts' expectations. The stock hit its 52-week high of $49.06 earlier in the session ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades ...

Trending: Former Mar-A-Lago Valet Trashes Trump's 'Witch Hunt' Argument: 'Can’t Take Responsibility' Must Read: Redditors Prefer Apple Stock Over NVIDIA, AMD, But A Death Cross Lurks See Also ...

Pier and beam foundations, one of the most common types of foundation in the U.S., are an excellent, affordable method of home building but remain prone to a host of erosion and water damage issues.